Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
bb2121 in relapsed/refractory and high-risk multiple myeloma
NCT03601078Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2018
- Primary completion
- Jan 2026
- Modality
- CAR-T Cells
- Countries
- 6
01
Overview
A Phase 2 trial of idecabtagene vicleucel in multiple myeloma (MM), sponsored by Celgene Corporation. Started Dec 2018; status: completed.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03601078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03601078.